Summary: The Centers for Medicare & Medicaid Services modified its Human Chorionic Gonadotropin coverage policy, effective May 15, 2026. Here's what billing teams need to know before that date.
CMS Human Chorionic Gonadotropin coverage policy changes don't come along often, but when they do, they ripple across multiple specialties — reproductive endocrinology, urology, oncology, and internal medicine all have skin in this game. The Centers for Medicare & Medicaid Services updated this policy with a May 15, 2026 effective date. The published policy does not list specific CPT or HCPCS codes in the available data, so your first step is pulling the full policy document from CMS directly and cross-referencing it against your current charge capture.
Quick-Reference Table
| Field | Detail |
|---|---|
| Payer | CMS |
| Policy | Human Chorionic Gonadotropin |
| Policy Code | N/A |
| Change Type | Modified |
| Effective Date | May 15, 2026 |
| Impact Level | Medium-High |
| Specialties Affected | Reproductive endocrinology, urology, oncology, internal medicine, obstetrics |
| Key Action | Pull the full CMS policy, audit your HCG-related claims, and verify medical necessity documentation before May 15, 2026 |
CMS Human Chorionic Gonadotropin Coverage Policy and Medical Necessity Requirements 2026
Human Chorionic Gonadotropin — HCG — sits at the intersection of fertility treatment, cancer monitoring, and diagnostic lab work. That broad clinical footprint is exactly why a modification to the CMS HCG coverage policy matters to more than one billing department.
CMS has used HCG coverage policy to draw a hard line between covered diagnostic use and non-covered off-label applications. Medical necessity is the central test. CMS does not reimburse HCG administration or testing simply because a clinician orders it — the clinical context has to match a covered indication.
The real issue here is documentation. For HCG-related claims, CMS expects your medical record to show a clear clinical rationale that ties the service to a covered diagnosis. Vague orders or missing clinical notes are the fastest path to a claim denial. Your billing team should treat documentation review as a pre-submission step, not a post-denial scramble.
Because the available policy data does not include specific codes, billing guidelines around exact CPT or HCPCS identifiers are difficult to detail here with precision. Pull the full policy from the CMS source before your billing team makes any workflow changes based on this post alone.
What CMS Historically Covers for HCG
CMS has historically covered HCG in three broad clinical contexts:
Diagnostic testing. HCG measurement is a standard part of pregnancy confirmation, ectopic pregnancy workup, and gestational trophoblastic disease monitoring. When the diagnosis codes support these indications, coverage is generally straightforward.
Oncology monitoring. HCG is a recognized tumor marker for testicular germ cell tumors and some other malignancies. Serial HCG testing in cancer monitoring has clear medical necessity support under Medicare's coverage frameworks.
Fertility treatment (limited). This is where coverage gets complicated. Medicare does not cover infertility treatment as a general rule. HCG injections used to trigger ovulation or support luteal phase in a fertility protocol are almost always non-covered. However, HCG prescribed for a covered indication — such as hypogonadotropic hypogonadism in male patients — can qualify for reimbursement under the right diagnosis coding.
That last category generates the most billing confusion, and it's where you'll see the most claim denial activity.
Prior Authorization and HCG
Prior authorization requirements for HCG vary by Medicare Administrative Contractor and plan type. Medicare Advantage plans impose their own prior auth rules on top of traditional Medicare guidelines, and those rules don't always match. If your practice serves Medicare Advantage patients who receive HCG therapy, verify prior authorization requirements with each plan individually.
Traditional Medicare generally does not require prior authorization for HCG lab tests in diagnostic contexts. Therapeutic HCG — the injectable product used in fertility or hormone replacement — is a different story. Some MACs have local coverage determination policies that govern injectable HCG for hypogonadism, and those LCDs may carry prior auth or documentation requirements your team needs to track.
CMS Human Chorionic Gonadotropin Exclusions and Non-Covered Indications
CMS is explicit about what HCG coverage does not include. These exclusions are consistent across the broader Medicare coverage framework, regardless of what this specific policy modification may have adjusted.
Infertility treatment. Medicare excludes infertility services from coverage. HCG used as part of an ovulation induction protocol — in any patient — falls outside Medicare's covered benefits. This applies even when a physician documents medical necessity. The exclusion is categorical, not evidence-based.
Weight loss. HCG injections marketed or prescribed for weight loss are not covered. CMS and the FDA have both addressed this directly. Any claim submitted with HCG in a weight loss context will be denied and could trigger additional scrutiny.
Off-label uses without clinical support. HCG prescribed for fatigue, anti-aging, or other off-label indications does not meet medical necessity under Medicare's standards. Claims for these services expose your practice to recoupment risk.
The distinction between a covered indication (hypogonadism in a male patient) and a non-covered one (general hormone optimization) often comes down to the ICD-10 code on the claim and the supporting documentation. Your billing team and medical director need to align on this before you submit.
Coverage Indications at a Glance
The specific policy data available for this update does not include a detailed breakdown of individual indications with assigned codes. The table below reflects the established CMS coverage framework for HCG based on Medicare policy history. Confirm each indication against the full policy document at the CMS source before using this as a billing guide.
| Indication | Status | Relevant Codes | Notes |
|---|---|---|---|
| Pregnancy confirmation / early pregnancy monitoring | Covered | Confirm with full policy | Standard diagnostic use; medical necessity documentation required |
| Gestational trophoblastic disease monitoring | Covered | Confirm with full policy | Oncology context; serial testing generally supported |
| Testicular germ cell tumor monitoring (tumor marker) | Covered | Confirm with full policy | Recognized tumor marker; ties to oncology diagnosis required |
| Male hypogonadotropic hypogonadism (therapeutic HCG) | Covered (with criteria) | Confirm with full policy | LCD requirements may apply; check your MAC's local coverage determination |
| Infertility treatment (any patient) | Not Covered | N/A | Categorical Medicare exclusion |
| Ovulation induction | Not Covered | N/A | Part of infertility exclusion |
| Weight loss programs | Not Covered | N/A | CMS and FDA both address this exclusion explicitly |
| Anti-aging / hormone optimization (off-label) | Not Covered | N/A | No medical necessity support under Medicare standards |
| Luteal phase support in ART cycles | Not Covered | N/A | Falls under infertility exclusion |
CMS Human Chorionic Gonadotropin Billing Guidelines and Action Items 2026
The effective date of May 15, 2026 gives your team a defined window to act. Don't let it pass without making these moves.
| # | Action Item |
|---|---|
| 1 | Pull the full CMS policy document now. The available data for this update does not include specific CPT or HCPCS codes. Access the full policy at the CMS source before May 15, 2026 to identify every code this modification affects. Your charge capture depends on having the actual code list. |
| 2 | Audit HCG claims from the past 12 months. Run a report on all claims that include HCG-related services — lab tests and therapeutic injectables both. Look for patterns: are your diagnosis codes consistently supporting medical necessity? Are any claims showing infertility-adjacent ICD-10 codes that could trigger a denial under this updated policy? |
| 3 | Review your MAC's local coverage determination. If your Medicare Administrative Contractor has an LCD governing HCG — particularly for therapeutic use in hypogonadism — pull that document alongside the CMS national policy. MACs can be more restrictive than the national policy. Regional variation here is real and it costs money when you miss it. |
| 4 | Align your medical director on documentation standards. The gap between a covered and a non-covered HCG claim often lives in the clinical note, not the code. Your physicians need to document the specific clinical indication that supports coverage. Generic notes citing "hormone replacement" or "low testosterone" without the underlying diagnosis are not enough. |
| 5 | Verify prior authorization requirements for Medicare Advantage patients. Each MA plan sets its own prior auth rules. For therapeutic HCG — injectable products for hypogonadism — confirm prior authorization requirements with every MA plan your practice contracts with before the effective date. |
| 6 | Update your payer matrix if you manage multiple payers. HCG coverage policy varies significantly between CMS, Aetna, Cigna, and UnitedHealthcare. A CMS modification is a good trigger to check whether your payer matrix accurately reflects each plan's current coverage status. If you're not sure where your matrix stands, talk to your billing consultant before May 15, 2026. |
| 7 | Brief your front desk and clinical staff on non-covered uses. Weight loss and off-label uses are where practices get into trouble. Your front desk should know to flag HCG requests that don't fit a covered diagnosis before the order hits your billing system. Prevention is cheaper than appeals. |
| Previous Version | Current Version |
|---|---|
| Coverage is considered experimental and investigational for all indications | Coverage is considered medically necessary when specific criteria are met |
| Prior authorization is not required | Prior authorization is required for initial treatment |
| Documentation must include clinical history | Documentation must include clinical history |
| Re-review every 24 months | Re-review every 12 months with updated clinical documentation |
CPT, HCPCS, and ICD-10 Codes for Human Chorionic Gonadotropin Under CMS Policy
The policy data available for this update does not include a specific list of CPT, HCPCS, or ICD-10 codes. Do not rely on inferred or assumed codes for Human Chorionic Gonadotropin billing without pulling the full CMS policy document.
Common HCG-related codes that appear in this clinical space include laboratory panel codes, individual HCG assay codes, and injectable drug codes — but this post will not list them here without confirmation from the actual policy data. Using unverified codes based on a policy summary creates billing risk, not billing accuracy.
Access the full policy at the CMS source linked in the Quick-Reference table. Cross-reference every code you currently use for HCG services against what CMS lists as covered, not covered, or subject to additional criteria under this modified policy.
If your compliance officer or billing consultant needs to review the code list before the effective date, build that into your pre-May 15, 2026 workflow now.
Get the Full Picture
Track this policy across versions, search 1,500+ policies by CPT code, and get real-time alerts when any payer changes coverage.